Overview

Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The pupose of this study is to demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma.

Phase:

Phase 2

Details

Lead Sponsor:

Light Sciences Oncology

Treatments:

Talaporfin